comparemela.com

Latest Breaking News On - றெபக்டோர் மூலதனம் - Page 3 : comparemela.com

Big Money for Gene Editing, Engineering, Structure-Based Drug Design, and Data Management

April 29, 2021 April 29, 2021 | Illumina joins the Gates Foundation in a global pathogen genomics initiative, new money for immune profiling, and Benchling nets $200M for their cloud platform.   $375M: Fund for Growth-Stage Medtech, Digital Health  Endeavour Vision has closed Endeavour Medtech Growth II (EMG II) LP at USD 375 million in capital commitments. The fund will pursue the same strategy as its predecessor: to support growth-stage medtech and digital health innovations that advance the standard of care and bring efficiencies to healthcare systems. Both new and returning investors supported EMG II LP, including public pension funds, multi-manager funds, family offices, and high-net-worth individuals. EMG II LP builds on Endeavour Vision’s two decades of healthcare investing, which to date has included over USD 500 million invested in 42 companies 21 of which have exited via an acquisition or IPO. The fund has already supported seven companies with investm

Temasek Invests in Solugen to Boost Asia Opportunities

Temasek Invests in Solugen to Boost Asia Opportunities Posted on 04/27/2021 Formed in 2016 by Gaurab Chakrabarti, M.D., Ph.D., and Sean Hunt, Ph.D., Solugen Inc. is a synthetic biology chemicals manufacturer. Singapore’s Temasek Holdings made an investment in Solugen to support further scaleup and sales growth of Solugen’s molecular manufacturing platform that harnesses biology to make high-performing, cost effective carbon negative chemicals, ingredients, and materials. Solugen believes Southeast Asia will be an ideal location to deploy its technology given the need for cleaner chemical products to support critical infrastructures such as clean water, agriculture, energy, and food/beverage.

Ophelia Raises $15m in Series A Funding

Ophelia, a NYC-based healthcare tech startup providing treatment for Opioid Use Disorder (OUD), raised $15m in Series A funding. The round was led by Menlo Ventures with participation from Y Combinator, General Catalyst, Refactor Capital, and the founders of Flatiron Health, Warby Parker, Harry’s, Allbirds, PillPack, Carbon Health, and Lambda School. The company intends to use the funds to continue to build and expand its services to patients across the U.S., to soon accept insurance, including Medicare and Medicaid. Led by Zack Gray, Co-founder and CEO, Ophelia offers an alternative to traditional rehab for the treatment of OUD. Through its telemedicine platform, the company provides Medication-Assisted Treatment (MAT) in a private way for patients who otherwise have no way to access care. MAT works through a combination of medication to stop opioid withdrawal and cravings, plus support and therapy for patients when helpful.

Mori Raises $16M in Series B Funding

Mori, a Boston, MA-based food technology company, raised $16m in Series B financing. The round was led by the Drawdown Fund with participation from previous investors Acre Venture Partners, The Engine, Prelude Ventures, Refactor Capital, Closed Loop Partners as well as new investor Knollwood Investment Advisory. The company intends to use the funds to accelerate commercialization into numerous categories and geographies, while expanding its product development pipeline. Led by Adam Behrens, CEO, Mori uses salt, water, and heat to extract protein from silk and create an all-natural and edible protective layer that keeps food fresher for longer. The patented technology can be integrated at any time from farm to shelf, allowing food producers, processors, and retailers to extend shelf life, reach new markets, and reduce waste.

Astranis Raises $250M in Series C Financing, Valuing at $1 4 Billion

Astranis Raises $250M in Series C Financing, Valuing at $1 4 Billion
finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.